• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Robust evidence of the rapid efficacy of benralizumab.

作者信息

Nagano Tatsuya

机构信息

Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

出版信息

J Thorac Dis. 2025 Jul 31;17(7):4376-4378. doi: 10.21037/jtd-2025-452. Epub 2025 Jul 29.

DOI:10.21037/jtd-2025-452
PMID:40809210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12340284/
Abstract
摘要

相似文献

1
Robust evidence of the rapid efficacy of benralizumab.贝那利珠单抗快速起效的有力证据。
J Thorac Dis. 2025 Jul 31;17(7):4376-4378. doi: 10.21037/jtd-2025-452. Epub 2025 Jul 29.
2
Anti-IL-5 therapies for asthma.哮喘的抗 IL-5 治疗。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD010834. doi: 10.1002/14651858.CD010834.pub4.
3
Anti-IL5 therapies for asthma.用于哮喘的抗白细胞介素-5疗法。
Cochrane Database Syst Rev. 2017 Sep 21;9(9):CD010834. doi: 10.1002/14651858.CD010834.pub3.
4
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.使用贝那利珠单抗治疗哮喘和慢性阻塞性肺疾病的嗜酸性粒细胞性加重（ABRA）：一项双盲、双模拟、活性安慰剂对照的随机试验。
Lancet Respir Med. 2025 Jan;13(1):59-68. doi: 10.1016/S2213-2600(24)00299-6. Epub 2024 Nov 29.
5
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.美泊利珠单抗、贝那利珠单抗和度匹鲁单抗治疗嗜酸性粒细胞性哮喘的疗效比较：一项贝叶斯网状荟萃分析。
J Allergy Clin Immunol. 2022 Nov;150(5):1097-1105.e12. doi: 10.1016/j.jaci.2022.05.024. Epub 2022 Jun 27.
6
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.特泽泊单抗对比美泊利珠单抗、贝那利珠单抗和度普利尤单抗治疗嗜酸性粒细胞性哮喘的疗效：一项贝叶斯网络荟萃分析。
J Allergy Clin Immunol. 2023 Mar;151(3):747-755. doi: 10.1016/j.jaci.2022.11.021. Epub 2022 Dec 17.
7
Population Pharmacokinetics and Exposure-Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma.倍利珠单抗在中国患有重度嗜酸性粒细胞性哮喘的成人、青少年和儿童参与者中的群体药代动力学及暴露-反应分析。
Clin Pharmacokinet. 2025 Jun 23. doi: 10.1007/s40262-025-01538-9.
8
Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.血清 IgE 浓度预测重度嗜酸性粒细胞性哮喘患者恶化风险和 benralizumab 疗效的能力。
Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14.
9
Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction.倍利珠单抗推进重度哮喘缓解：最新发现、当前观点及未来方向
Clin Exp Allergy. 2025 Jul;55(7):521-531. doi: 10.1111/cea.70083. Epub 2025 May 30.
10
Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma.在未控制的嗜酸性粒细胞性哮喘背景下，贝那利珠单抗对暴发性嗜酸性粒细胞性心肌炎的快速疗效。
J Cardiol Cases. 2023 Jun 14;28(3):100-104. doi: 10.1016/j.jccase.2023.04.012. eCollection 2023 Sep.

本文引用的文献

1
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.使用贝那利珠单抗治疗哮喘和慢性阻塞性肺疾病的嗜酸性粒细胞性加重（ABRA）：一项双盲、双模拟、活性安慰剂对照的随机试验。
Lancet Respir Med. 2025 Jan;13(1):59-68. doi: 10.1016/S2213-2600(24)00299-6. Epub 2024 Nov 29.
2
Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.导致 benralizumab 具有强大抗嗜酸性粒细胞活性的新作用机制。
Eur Respir J. 2022 Mar 3;59(3). doi: 10.1183/13993003.04306-2020. Print 2022 Mar.
3
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
贝那鲁肽治疗重度嗜酸性粒细胞性哮喘患者的疗效发作和对健康相关生活质量的影响、恶化率、肺功能和鼻息肉症状：一项随机、对照、3b 期试验。
Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22.
4
Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma.美泊利单抗、贝那利珠单抗和泼尼松龙治疗嗜酸性粒细胞性哮喘的血液嗜酸性粒细胞清除情况
Am J Respir Crit Care Med. 2020 Nov 1;202(9):1314-1316. doi: 10.1164/rccm.202003-0729LE.
5
The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach.贝那利珠单抗在治疗近乎致命性哮喘中的应用：一种新方法。
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1441-1443. doi: 10.1164/rccm.202001-0093LE.
6
Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.贝那鲁肽对严重未控制哮喘患者晨峰呼气流速的快速作用。
Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23.
7
Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma.贝那鲁肽暴露与重症嗜酸性哮喘患者疗效的关系。
Clin Pharmacol Ther. 2019 Aug;106(2):383-390. doi: 10.1002/cpt.1371. Epub 2019 Mar 22.
8
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.贝那鲁肽在重症哮喘中的糖皮质激素节省作用。
N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22.
9
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.贝那鲁肽治疗高剂量吸入性皮质激素和长效β-agonists 控制不佳的严重哮喘患者的疗效和安全性（SIROCCO）：一项随机、多中心、安慰剂对照的 3 期临床试验。
Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5.
10
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.贝那利珠单抗，一种抗白细胞介素-5 受体 α 的单克隆抗体，作为附加治疗用于严重、未控制、嗜酸性粒细胞性哮喘（CALIMA）患者：一项随机、双盲、安慰剂对照的 3 期试验。
Lancet. 2016 Oct 29;388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8. Epub 2016 Sep 5.